Sicart Associates LLC Purchases 130 Shares of Illumina, Inc. (NASDAQ:ILMN)

Sicart Associates LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 0.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,862 shares of the life sciences company’s stock after purchasing an additional 130 shares during the period. Illumina comprises approximately 2.9% of Sicart Associates LLC’s holdings, making the stock its 11th largest holding. Sicart Associates LLC’s holdings in Illumina were worth $8,328,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Versant Capital Management Inc raised its position in shares of Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. purchased a new stake in shares of Illumina during the second quarter valued at $34,000. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina in the second quarter valued at about $61,000. Finally, Mizuho Securities Co. Ltd. acquired a new stake in shares of Illumina during the 2nd quarter valued at about $63,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Up 1.4 %

Shares of ILMN stock traded up $1.98 during trading hours on Tuesday, reaching $146.01. 555,864 shares of the stock traded hands, compared to its average volume of 1,990,270. The business has a fifty day moving average price of $134.69 and a 200 day moving average price of $121.67. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $151.40. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $23.26 billion, a PE ratio of -17.67 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. Illumina’s revenue was down 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 earnings per share. On average, equities research analysts forecast that Illumina, Inc. will post 3.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ILMN. JPMorgan Chase & Co. decreased their price objective on shares of Illumina from $130.00 to $125.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Barclays increased their target price on Illumina from $125.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 15th. Piper Sandler cut their target price on Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Finally, Scotiabank dropped their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.33.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.